Literature DB >> 21947356

Effect of lamotrigine and carbamazepine on corticotropin-releasing factor-associated serotonergic transmission in rat dorsal raphe nucleus.

Shunske Tanahashi1, Satoshi Yamamura, Masanori Nakagawa, Eishi Motomura, Motohiro Okada.   

Abstract

Corticotropin-releasing factor (CRF) and serotonin are important transmitters of the pathophysiology of mood disorder. To clarify the mechanisms of action of lamotrigine (LTG) and carbamazepine (CBZ), we determined their effects on serotonin release associated with CRF in rat dorsal raphe nucleus (DRN) and median prefrontal cortex (mPFC) using dual-probe microdialysis. Neither perfusion with CRF1 nor CRF2 antagonists into DRN-affected serotonin release in DRN and mPFC. Perfusion of 10 μM CRF into DRN increased serotonin release in both regions, whereas 0.1 μM CRF decreased and had no effect on serotonin release in DRN and mPFC, respectively. Pre-perfusion with CRF1 antagonist into DRN inhibited 0.1 μM CRF-induced serotonin reduction, whereas pre-perfusion with CRF2 antagonist in DRN inhibited 10 μM CRF-induced serotonin elevation, without affecting 0.1 μM CRF-induced serotonin reduction. LTG perfusion concentration dependently decreased serotonin releases in DRN and mPFC. Therapeutic and supratherapeutic concentrations of CBZ increased and decreased serotonin releases in both regions, respectively. Pre-perfusion with sub-therapeutic concentration LTG inhibited CRF1-induced serotonin reduction without affecting CRF2-induced serotonin release, whereas pre-perfusion with therapeutic concentration of LTG inhibited both CRF1- and CRF2-actions. In contrast, both therapeutic and supratherapeutic concentrations of CBZ inhibited CRF2-induced serotonin release without affecting CRF1-induced serotonin reduction. Neither LTG nor CBZ affected the CRF-induced cAMP production in cells over-expressing CRF1 and CRF2 receptors. This study demonstrated that inhibition of CRF2-receptor-mediated serotonergic transmission is a mechanism shared by LTG and CBZ, two clinically related compounds, whereas LTG but not CBZ inhibits CRF1-receptor-mediated serotonergic transmission. Therefore, these mechanisms may contribute to the clinical actions of these agents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21947356     DOI: 10.1007/s00213-011-2506-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  63 in total

1.  Regulation of serotonin release in the lateral septum and striatum by corticotropin-releasing factor.

Authors:  M L Price; I Lucki
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

Review 2.  Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists.

Authors:  Florian Holsboer; Marcus Ising
Journal:  Eur J Pharmacol       Date:  2008-01-24       Impact factor: 4.432

3.  Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists.

Authors:  C Chen; R Dagnino; E B De Souza; D E Grigoriadis; C Q Huang; K I Kim; Z Liu; T Moran; T R Webb; J P Whitten; Y F Xie; J R McCarthy
Journal:  J Med Chem       Date:  1996-10-25       Impact factor: 7.446

4.  Microdialysis probes calibration: gradient and tissue dependent changes in no net flux and reverse dialysis methods.

Authors:  A Le Quellec; S Dupin; P Genissel; S Saivin; B Marchand; G Houin
Journal:  J Pharmacol Toxicol Methods       Date:  1995-02       Impact factor: 1.950

5.  Effects of combined lamotrigine and valproate on basal and stimulated extracellular amino acids and monoamines in the hippocampus of freely moving rats.

Authors:  Shagufta Ahmad; Leslie J Fowler; Peter S Whitton
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-01-20       Impact factor: 3.000

6.  A blinded, randomized comparison of immediate-release and extended-release carbamazepine capsules in manic and depressed bipolar subjects.

Authors:  Rif S El-Mallakh; Mary Ruth Salem; Amarjit Chopra; Gregory J Mickus; Praveen Penagaluri; Radhika Movva
Journal:  Ann Clin Psychiatry       Date:  2010-02       Impact factor: 1.567

Review 7.  Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders.

Authors:  D P Behan; D E Grigoriadis; T Lovenberg; D Chalmers; S Heinrichs; C Liaw; E B De Souza
Journal:  Mol Psychiatry       Date:  1996-09       Impact factor: 15.992

Review 8.  Getting closer to affective disorders: the role of CRH receptor systems.

Authors:  Marianne B Müller; Wolfgang Wurst
Journal:  Trends Mol Med       Date:  2004-08       Impact factor: 11.951

9.  Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide.

Authors:  Glenn R Valdez; Koki Inoue; George F Koob; Jean Rivier; Wylie Vale; Eric P Zorrilla
Journal:  Brain Res       Date:  2002-07-05       Impact factor: 3.252

10.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Ayal Schaffer; Sagar V Parikh; Serge Beaulieu; Claire O'Donovan; Glenda MacQueen; Roger S McIntyre; Verinder Sharma; Arun Ravindran; L Trevor Young; Allan H Young; Martin Alda; Roumen Milev; Eduard Vieta; Joseph R Calabrese; Michael Berk; Kyooseob Ha; Flávio Kapczinski
Journal:  Bipolar Disord       Date:  2009-05       Impact factor: 6.744

View more
  7 in total

1.  Differential mechanisms underlie the regulation of serotonergic transmission in the dorsal and median raphe nuclei by mirtazapine: a dual probe microdialysis study.

Authors:  Kouji Fukuyama; Shunske Tanahashi; Tatsuya Hamaguchi; Masanori Nakagawa; Takashi Shiroyama; Eishi Motomura; Motohiro Okada
Journal:  Psychopharmacology (Berl)       Date:  2013-05-09       Impact factor: 4.530

2.  Dissociation of μ-opioid receptor and CRF-R1 antagonist effects on escalated ethanol consumption and mPFC serotonin in C57BL/6J mice.

Authors:  Lara S Hwa; Akiko Shimamoto; Tala Kayyali; Kevin J Norman; Rita J Valentino; Joseph F DeBold; Klaus A Miczek
Journal:  Addict Biol       Date:  2014-09-28       Impact factor: 4.280

3.  Chronic activation of corticotropin-releasing factor type 2 receptors reveals a key role for 5-HT1A receptor responsiveness in mediating behavioral and serotonergic responses to stressful challenge.

Authors:  Adi Neufeld-Cohen; Paul A T Kelly; Evan D Paul; Roderick N Carter; Elizabeth Skinner; Henry J Olverman; Joan M Vaughan; Orna Issler; Yael Kuperman; Christopher A Lowry; Wylie W Vale; Jonathan R Seckl; Alon Chen; Pauline M Jamieson
Journal:  Biol Psychiatry       Date:  2012-06-15       Impact factor: 13.382

4.  Lurasidone Sub-Chronically Activates Serotonergic Transmission via Desensitization of 5-HT1A and 5-HT7 Receptors in Dorsal Raphe Nucleus.

Authors:  Motohiro Okada; Kouji Fukuyama; Ruri Okubo; Takashi Shiroyama; Yuto Ueda
Journal:  Pharmaceuticals (Basel)       Date:  2019-10-06

5.  Effects of Subchronic Administrations of Vortioxetine, Lurasidone, and Escitalopram on Thalamocortical Glutamatergic Transmission Associated with Serotonin 5-HT7 Receptor.

Authors:  Motohiro Okada; Ryusuke Matsumoto; Yoshimasa Yamamoto; Kouji Fukuyama
Journal:  Int J Mol Sci       Date:  2021-01-29       Impact factor: 5.923

Review 6.  Astroglial Connexin43 as a Potential Target for a Mood Stabiliser.

Authors:  Motohiro Okada; Tomoka Oka; Misaki Nakamoto; Kouji Fukuyama; Takashi Shiroyama
Journal:  Int J Mol Sci       Date:  2020-12-30       Impact factor: 5.923

7.  Vortioxetine Subchronically Activates Serotonergic Transmission via Desensitization of Serotonin 5-HT1A Receptor with 5-HT3 Receptor Inhibition in Rats.

Authors:  Motohiro Okada; Ruri Okubo; Kouji Fukuyama
Journal:  Int J Mol Sci       Date:  2019-12-10       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.